Criteria for environmentally associated autoimmune diseases

Journal of Autoimmunity

Volumn 39, Issue 4, 2012, Pages 253-258

  Miller, Frederick W ^a   Pollard, K Michael ^b   Parks, Christine G ^a   Germolec, Dori R ^a   Leung, Patrick S C ^c   Selmi, Carlo ^c,d   Humble, Michael C ^a   Rose, Noel R ^e  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Autoimmune disease; Criteria; Environmental risk factors

Indexed keywords

ENVIRONMENTAL CHEMICAL;

AUTOIMMUNE DISEASE; CLINICAL PRACTICE; DISEASE CLASSIFICATION; ENVIRONMENTAL FACTOR; EPIGENETICS; GENETIC RISK; HUMAN; LABORATORY TEST; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS;

AUTOIMMUNE DISEASES; CONGRESSES AS TOPIC; ENVIRONMENT; ENVIRONMENTAL EXPOSURE; EPIGENESIS, GENETIC; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; RESEARCH DESIGN; RISK FACTORS;

EID: 84869864007     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2012.05.001     Document Type: Review

References (44)

1. Cooper G.S., Bynum M.L., Somers E.C. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun 2009, 33:197-207.
2. Rose N.R., Bona C. Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol Today 1993, 14:426-430.
3. Cooper G.S., Miller F.W. Environmental influences on autoimmunity and autoimmune diseases. Immunotoxicology and immunopharmacology 2007, 437-454. CRC Press, New York. R. Luebke (Ed.).
4. WHO Task Group on Environmental Health Criteria Environmental health criteria 236. Principles and methods for assessing autoimmunity associated with exposure to chemicals 2006, WHO, p. 1-324.
5. Chang C., Gershwin M.E. Drug-induced lupus erythematosus: incidence, management and prevention. Drug Saf 2011, 34:357-374.
6. Gelpi E., de la Paz M.P., Terracini B., Abaitua I., de la Cámara A.G., Kilbourne E.M., et al. The Spanish toxic oil syndrome 20 years after its onset: a multidisciplinary review of scientific knowledge. Environ Health Perspect 2002, 110:457-464.
7. Hertzman P.A., Clauw D.J., Kaufman L.D., Varga J., Silver R.M., Thacker H.L., et al. The eosinophilia-myalgia syndrome: status of 205 patients and results of treatment 2 years after onset. Ann Intern Med 1995, 122:851-855.
8. Hill A.B. The environment and disease: association or causation?. Proc R Soc Med 1965, 58:295-300.
9. Kaufman L.D., Gleich G.J. Eosinophilia myalgia syndrome. Rheumatic diseases and the environment 1999, 55-73. Arnold. L.D. Kaufman, J. Varga (Eds.).
10. Miller F.W., Hess E.V., Clauw D.J., Hertzman P.A., Pincus T., Silver R.M., et al. Approaches for identifying and defining environmentally associated rheumatic disorders. Arthritis Rheum 2000, 43:243-249.
11. Bannwarth B. Drug-induced musculoskeletal disorders. Drug Saf 2007, 30:27-46.
12. Pollard K.M., Hultman P., Kono D.H. Toxicology of autoimmune diseases. Chem Res Toxicol 2010.
13. Scherer K., Spoerl D., Bircher A.J. Adverse drug reactions to biological response modifiers. J Dtsch Dermatol Ges 2010.
14. Miller F.W. Environmental agents and autoimmune diseases. Adv Exp Med Biol 2011, 711:61-81.
15. Klareskog L., Padyukov L., Alfredsson L. Smoking as a trigger for inflammatory rheumatic diseases. Curr Opin Rheumatol 2007, 19:49-54.
16. Otsuki T., Maeda M., Murakami S., Hayashi H., Miura Y., Kusaka M., et al. Immunological effects of silica and asbestos. Cell Mol Immunol 2007, 4:261-268.
17. Price J.M., Gates G.S. "Junk science" in the courtroom. Causes and effects. ASAIO J 1995, 41:139-142.
18. Parks C.G., Cooper G.S. Occupational exposures and risk of systemic lupus erythematosus. Autoimmunity 2005, 38:497-506.
19. Jayapal M., Bhattacharjee R.N., Melendez A.J., Hande M.P. Environmental toxicogenomics: a post-genomic approach to analysing biological responses to environmental toxins. Int J Biochem Cell Biol 2010, 42:230-240.
20. Rubin R.L. Drug-induced lupus. Toxicology 2005, 209:135-147.
21. Burlingame R.W., Rubin R.L. Drug-induced anti-histone autoantibodies display two patterns of reactivity with substructures of chromatin. J Clin Invest 1991, 88:680-690.
22. Bakhtiar R. Biomarkers in drug discovery and development. J Pharmacol Toxicol Methods 2008, 57:85-91.
23. Mahadevan B., Snyder R.D., Waters M.D., Benz R.D., Kemper R.A., Tice R.R., et al. Genetic toxicology in the 21st century: reflections and future directions. Environ Mol Mutagen 2011, 52:339-354.
24. Duramad P., Holland N.T. Biomarkers of immunotoxicity for environmental and public health research. Int J Environ Res Public Health 2011, 8:1388-1401.
25. Wetmore B.A., Wambaugh J.F., Ferguson S.S., Sochaski M.A., Rotroff D.M., Freeman K., et al. Integration of dosimetry, exposure and high-throughput screening data in chemical toxicity assessment. Toxicol Sci 2011.
26. Tan E.M. Antinuclear antibodies: diagnostic markers for autoimmune diseases and probes for cell biology. Adv Immunol 1989, 44:93-151.
27. Rubin R.L., Burlingame R.W., Arnott J.E., Totoritis M.C., McNally E.M., Johnson A.D. IgG but not other classes of anti-[(H2A-H2B)-DNA] is an early sign of procainamide-induced lupus. J Immunol 1995, 154:2483-2493.
28. Balboni I., Limb C., Tenenbaum J.D., Utz P.J. Evaluation of microarray surfaces and arraying parameters for autoantibody profiling. Proteomics 2008, 8:3443-3449.
29. Graham K.L., Robinson W.H., Steinman L., Utz P.J. High-throughput methods for measuring autoantibodies in systemic lupus erythematosus and other autoimmune diseases. Autoimmunity 2004, 37:269-272.
30. Tabakman S.M., Lau L., Robinson J.T., Price J., Sherlock S.P., Wang H., et al. Plasmonic substrates for multiplexed protein microarrays with femtomolar sensitivity and broad dynamic range. Nat Commun 2011, 2:466.
31. Utz P.J. Protein arrays for studying blood cells and their secreted products. Immunol Rev 2005, 204:264-282.
32. Kattah M.G., Coller J., Cheung R.K., Oshidary N., Utz P.J. HIT: a versatile proteomics platform for multianalyte phenotyping of cytokines, intracellular proteins and surface molecules. Nat Med 2008, 14:1284-1289.
33. Chan S.M., Ermann J., Su L., Fathman C.G., Utz P.J. Protein microarrays for multiplex analysis of signal transduction pathways. Nat Med 2004, 10:1390-1396.
34. Pollard K.M., Pearson D.L., Hultman P., Hildebrandt B., Kono D.H. Lupus-prone mice as models to study xenobiotic-induced acceleration of systemic autoimmunity. Environ Health Perspect 1999, 107(Suppl. 5):729-735.
35. Chang C., Gershwin M.E. Drugs and autoimmunity-a contemporary review and mechanistic approach. J Autoimmun 2010, 34:J266-J275.
36. Okada S., Kamb M.L., Pandey J.P., Philen R.M., Love L.A., Miller F.W. Immunogenetic risk and protective factors for L-tryptophan associated eosinophilia-myalgia syndrome. Arthritis Rheum 2009, 61:1305-1311.
37. Miller F.W. Genetics of environmentally-associated rheumatic disease. Rheumatic diseases and the environment 1999, 33-45. Arnold Publishers, London. L.D. Kaufman, J. Varga (Eds.).
38. Hertzman P.A., Clauw D.J., Duffy J., Medsger T.A., Feinstein A.R. Rigorous new approach to constructing a gold standard for validating new diagnostic criteria, as exemplified by the eosinophilia-myalgia syndrome. Arch Intern Med 2001, 161:2301-2306.
39. Kallberg H., Ding B., Padyukov L., Bengtsson C., Rönnelid J., Klareskog L., et al. Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke. Ann Rheum Dis 2011, 70:508-511.
40. Portanova J.P., Arndt R.E., Tan E.M., Kotzin B.L. Anti-histone antibodies in idiopathic and drug-induced lupus recognize distinct intrahistone regions. J Immunol 1987, 138:446-451.
41. Strickland F.M., Richardson B.C. Epigenetics in human autoimmunity. Epigenetics in autoimmunity - DNA methylation in systemic lupus erythematosus and beyond. Autoimmunity 2008, 41:278-286.
42. Miller F.W., Alfredsson L., Costenbader K.H., Kamen D.L., Nelson L.M., Norris J.M., et al. Epidemiology of environmental exposures and human autoimmune disease: Findings from a National Institute of Environmental Health Sciences Expert Panel Workshop. J Autoimmun 2012, 39(4):259-271.
43. Selmi C., Leung P.S.C., Sherr D.H., Diaz M., Nyland J.F., Monestier M., et al. Mechanisms of environmental influence on human autoimmunity: A National Institute of Environmental Health Sciences Expert Panel Workshop. J Autoimmune 2012, 39(4):272-284.
44. Germolec D., Kono D.H., Dfau J.C., Pollard K.M. Animal models used to examine the role of the environment in the development of autoimmune disease: Findings from a National Institute of Environmental Health Sciences Expert Panel Workshop. J Autoimmune 2012, 39(4):285-293.